



DiaSys

Diagnostic Systems



Dialog

DiaSys International Newsletter

ISSUE 2022/01

Editorial	2
Humanitarian aid for Ukraine	3
New distributor in Tunisia	4
Great success at MedLab Middle East 2022	5
Long COVID- Recovered, but not yet healthy	6
Change of multi-purpose kit concepts	8
E-labeling - Change is on the way	9
Change of lid colors for calibrators and controls	10

Dear customers and friends,

Every now and then, it is not easy to find the right words for an editorial without getting emotional. During unstable times, it sometimes seems best to stick to familiar topics and let all politics aside.

We would like to thank everyone who attended this year's Medlab in Dubai and who paid us a visit at the DiaSys booth. It was great to meet each other face to face. The next show lies ahead, and we are more than happy to welcome you at our booth during Euromedlab in Munich.

Until then, we share product updates, additional information and the latest developments on Long Covid, including, of course, how DiaSys products will help to find the right answers.

We are pleased to welcome PROVISION Labs' Solutions as our new distributor in Tunisia as a member of the DiaSys family.

We wish you to stay healthy and that you and your families and friends remain safe.

Sincerely yours,
Dr. Jan Gorka

Author



Dr. Jan Gorka
Managing Director and CEO



Humanitarian aid for Ukraine

Hardly anyone can ignore the news and pictures of the present situation in Ukraine. Not only for the refugees, but especially for the population remaining in the war zone, fast help in all areas is essential to their survival.

The willingness to help is very strong, at DiaSys Diagnostic Systems, too. Along with the German sales subsidiary DiaSys Deutschland-Vertriebs-GmbH, the management donates a sum in the five-digit range to UNO-Flüchtlingshilfe e.V. in Bonn. In addition, a generous donation of clinical chemistry products will be sent on its way to Ukraine.

Thanks to the involvement of Ms. Inna Dmitrenko-Krüsemann, DiaSys representative for the Ukraine, and to the family network of the former sales manager, Dr. Michael Sprinzel, several pallets of urgently needed laboratory reagents, calibrators and controls will be transported directly to a hospital in Uzhgorod, where they will be distributed to surrounding hospitals as appropriate.

By donating these funds, DiaSys hopes to make a small contribution to those who currently need it most.

Author



Dr. Jan Gorka
Managing Director and CEO

New distributor in Tunisia

DiaSys recently appointed PROVISION Labs' Solutions as their exclusive distributor in Tunisia. With more than 10 years of experience in lab equipment, PROVISION Labs' Solutions has decided to diversify their portfolio by entering the clinical chemistry business.

On his first approach to DiaSys during MEDICA 2021, Mr. Marouen Akermi, one of the owners, explained their all-time goal to offer high quality products to their market to Mr. Christophe Bayet, General Manager Global Business of DiaSys. As DiaSys offers a global reputation as premium supplier with an excellent feedback from the Tunisian market, Mr. Akermi has decided very quickly to go ahead and extend their portfolio with DiaSys products.

To follow this new strategy, his team has been strengthened by a new CEO (Mr. Marouane Chebbi), a new Technical Director (Mr. Walid Nass), and a group of renowned biologists spread all over the country, which will support the company with their expertise. We welcome PROVISION Labs' Solutions as a new member in the DiaSys Family and wish them lot of success!

www.provision-labs.com



Above from left: Mr. Chebbi, Mr. Bayet, Mr. Akermi

Author



Christophe Bayet
General Manager Global Business / Head of Sales



Great success at MedLab Middle East 2022

After we could not exhibit at the MedLab Middle East last year due to the pandemic, we were even more excited to be back this year at the world's largest and most important trade fair in the laboratory and diagnostic sector.

DiaSys was happy to welcome many existing business partners, as well as new potential customers at our booth – everything whilst respecting the local pandemic rules to ensure everyone's health and safety.

Four intensive days, countless meetings, and interesting encounters are behind us. From January 21st to 24th, DiaSys digitally presented new and exciting innovations, which attracted great interest among the attending visitors.


We thank all visitors for their significant positive feedback, many interesting discussions and are looking forward to seeing you next year again.



Author



Isabella Wieland
Strategic Product Manager Reagents



Long COVID - Recovered, but not yet healthy

While the majority of patients fully recover from COVID-19, a significant number experience long-term health consequences. A study of 273,618 COVID-19 survivors published in PLOS medicine (1) has revealed that one out of three patients has shown clinical features of long COVID even three up to six months after their COVID-19 diagnosis.


The NICE guideline on long COVID (2) defines long COVID syndrome as symptoms that develop during or following an infection with COVID-19 and continue for more than 12 weeks. The full clinical picture of long COVID is complex and far from being understood. It comprises a constellation of heterogeneous symptoms with unclear cause and uncertain direct association with SARS-CoV-2 infection.

More than 50 long-term symptoms have been documented (3); the most frequent ones are fatigue, anosmia and dyspnea, headaches, and attention deficit. Factors like female sex, older age, active smoking or a severe, acute illness are associated with a higher risk to develop “long COVID”.

Currently, no laboratory test definitively distinguishes long COVID conditions from other etiologies, partly due to the heterogeneity of post COVID conditions. In the follow-up of recovered patients with post-acute consequences, clinical tests provide reliable support to identify the causes of ongoing symptoms and, most importantly, rule out serious diseases. In patients with ongoing symptoms, a basic panel of laboratory tests should be taken into consideration, which include tests for comorbidities that may contribute to the disease.

Author

Irene Delseith-Hermsdorf
Global Marketing - Head of Marketing



Long COVID- Recovered, but not yet healthy

Guidelines recommend assessing a basic panel including electrolytes, renal and liver function tests, transaminases CRP and Ferritin in all long COVID patients.

A study (4) has revealed that more than a quarter of patients having recovered from COVID-19, have shown elevated D-dimer levels up to four months after diagnosis. Since elevated D-dimer levels increase the long-term risk for a thromboembolic disease, it is recommended to observe this marker during post COVID monitoring in justified cases as well.

1. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, et al. (2021) Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLOS Medicine* 18(9): e1003773. <https://doi.org/10.1371/journal.pmed.1003773>
2. National Institute for Health and Care Excellence, Royal College of General Practitioners, Healthcare Improvement Scotland SIGN. COVID-19 rapid guideline: managing the long term effects of COVID-19. 2020. www.nice.org.uk/guidance/ng188.
3. Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep* 11, 16144 (2021). <https://doi.org/10.1038/s41598-021-95565-8>
4. Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. *J Thromb Haemost.* 2021;19:1064–1070. <https://doi.org/10.1111/jth.15267>

Author

Irene Delseith-Hermsdorf
Global Marketing - Head of Marketing



Change of multi-purpose kit concept

Due to the changes coming along with implementing the new IVDR (European Regulation for in-vitro diagnostics) by May 26, 2022, DiaSys has been obliged to some alterations in their product portfolio.

Thus, the concept for all multi-purpose kits containing a standard has been changed. Aqueous standards have been removed from the kit, at the same time the reagent volume in these kits has been increased as follows:

Reagent format	Previous kit concept	New kit concept
Monoreagents	5 x 25 mL	6 x 25 mL
2-component reagents	4 x 20 mL + 1 x 20 mL	5 x 20 mL + 1 x 25 mL
2-component reagents	3 x 20 mL + 2 x 15 mL	4 x 20 mL + 2 x 20 mL

The new kit concept has been implemented in January 2022. During a transitory period, DiaSys will continue to sell off remaining stocks of kits with standard.

The standards will still be available as separate kits. Please refer to our website for order information and available package inserts

<https://www.diasys-diagnostics.com/products/calibratorscontrols/standards/>

Author

Irene Delseith-Hermsdorf
Global Marketing - Head of Marketing

E-labeling - Change is on the way

Package inserts and instructions for use (IFUs) are the primary mechanism by which diagnostic manufacturers communicate important information about their products to healthcare professionals in accordance with national requirements.

Since the revision of documents, which may occur more than once a year, is time-consuming and there is a delay between updating the information and making it available to users, DiaSys has decided to switch to e-labeling.

E labeling refers to the fact that package inserts/IFUs as well as other product related documents such as safety data sheets or the symbol list are made available digitally only. Thus, changes to content or implementation of additional regulatory requirements may be realized immediately, as documents are accessible 24/7. Instead of re-printing and distributing costly hard-copy versions, updates are feasible with a minimum of additional cost and time.

E-labeling offers manufacturers and users many opportunities and advantages:

- Content consistency across markets
- Real-time update
- Cost-efficiency
- Reduction of DiaSys's ecological global footprint
- Enhanced reliability
- Prevention of recall due to labeling errors
- Great transparency and traceability
- Permanent availability

Along with the implementation of e-labeling in the second quarter of 2022, DiaSys will introduce a search function on the website by which customers are guided directly to the required document.


Author

Irene Delseith-Hermsdorf
Global Marketing - Head of Marketing

Change of lid colors for calibrators and controls

DiaSys will introduce new lid colors for the vials of calibrators and controls to avoid possible risks of mixing up the vials when in use. It is important to know that only the lid color will change; other properties will remain unchanged in their appearance and quality. The general uniform color concept is depicted below. DiaSys expects improving identification and recognition by this clear color standardisation.

Calibrator set



- Calibrator level 0 orange
- Calibrator level 1 blue
- Calibrator level 2 yellow
- Calibrator level 3 white
- Calibrator level 4 green
- Calibrator level 5 red

Controls



- Control level 1 or "N-normal" blue
- Control level 2 or "P-pathological" yellow

Lid colors for TruCal Lp(a), TruLab Lp(a), TruLab Urine Level 1 and 2, TruCal D-Dimer and TruLab D-Dimer remain unchanged. The changeover to the new color concept will begin in the 1st quarter of 2022. During a transitional period, both the old and the new color system will be available, as existing stocks of calibrators and controls with the old color concept have to be sold off.

As this new lid color concept might create registration or similar inconvenience at your end, we ask you to check the regulatory requirements associated with the changeover as soon as possible.

Author



David Ehlers
Product Manager Systems




Pay us a visit

April 10 – 14, 2022
Booth no. B226



30 years of DiaSys

In 2021, DiaSys celebrated its 30th company anniversary. An 'Inside DiaSys blog' has been established on the website, featuring ongoing articles from staff editors on 'the early days' and global growth. [Enjoy reading!](#)



DiaSys Diagnostic Systems GmbH
Alte Strasse 9
65558 Holzheim
Germany

Phone: +49 6432 9146-0
Fax: +49 6432 9146-32

www.diasys-diagnostics.com

